

This article was downloaded by:

On: 26 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Organic Preparations and Procedures International

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t902189982>

PREPARATION OF 5,10,11,11a-TETRAHYDRO-1H, 3H-THIAZOLO[2,3-c]- AND 5,10,11,11a-TETRAHYDRO-1H, 3H-THIAZOLO[4,3-c]- [1,4]BENZODIAZEPINES

Alexey B. Dyatkin^a; Bruce E. Maryanoff^a

^a Drug Discovery Johnson & Johnson Pharmaceutical Research & Development, Spring House, PA, USA

To cite this Article Dyatkin, Alexey B. and Maryanoff, Bruce E. (2002) 'PREPARATION OF 5,10,11,11a-TETRAHYDRO-1H, 3H-THIAZOLO[2,3-c]-AND 5,10,11,11a-TETRAHYDRO-1H, 3H-THIAZOLO[4,3-c]-[1,4]BENZODIAZEPINES', Organic Preparations and Procedures International, 34: 6, 652 – 655

To link to this Article: DOI: 10.1080/00304940209355788

URL: <http://dx.doi.org/10.1080/00304940209355788>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.


The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

PREPARATION OF 5,10,11,11a-TETRAHYDRO-1H,3H-THIAZOLO[2,3-c]-
AND 5,10,11,11a-TETRAHYDRO-1H,3H-THIAZOLO[4,3-c]-
[1,4]BENZODIAZEPINES

Submitted by Alexey B. Dyatkin* and Bruce E. Maryanoff
(03/06/02)

Drug Discovery
Johnson & Johnson Pharmaceutical Research & Development
Spring House, PA 19477-0776, USA

Benzodiazepines are perceived as "privileged" heterocyclic scaffolds for the genesis of drug candidates because this subunit tends to confer interesting biological activity to molecules.¹⁻⁷ For example, benzodiazepines are important components of anxiolytics,¹ vasopressin receptor antagonists,^{2,3} non-opioid analgesics,⁴ and cholecystokinin receptor antagonists.⁵ Additionally, pyrrolo[1,4] benzodiazepine antibiotics have attracted attention as potent anticancer agents.⁶ Although the syntheses of a variety of benzodiazepines are well documented, preparations of heterocyclic systems **4** and **7** are unknown. Since we needed intermediates **4** and **7** for a medicinal chemistry project, we developed convenient synthetic methods, which are reported herein.



The main synthetic approaches to amino acid-derived tricyclic benzodiazepinediones are based on acylation of a cyclic amino acid ester with *o*-nitrobenzoyl chloride, followed by tandem reduction-cyclization reaction,⁸⁻¹⁰ or on condensation of proline with isatoic anhydride.⁸⁻¹⁰ Previously, Carabateas⁸⁻¹⁰ reported the preparation of **3** in 48% yield by using the first route. However, our synthesis is based on the latter synthetic approach. One challenge in the synthesis of benzodiazepinediones **3** and **6** is the acid sensitivity of the starting materials and final products. To overcome this difficulty, we performed the condensation in a 4:1 mixture of dimethylformamide (DMF) and triethylamine (TEA). We found that heating a 1:1 mixture of isatoic anhydride and thiazolidinecarboxylic acids **2** and **5** in DMF-TEA affords moderate yields of benzodiazepinone **3** or **6**, respectively, in a simple reaction work-up. Our attempts to perform this reaction in either DMF or pyridine resulted in a

mixture of products. The benzodiazepinediones **3** and **6** were reduced to the corresponding amines **4** and **7** in good yields with lithium aluminum hydride in THF at 0°.

Starting with (-)-(*R*)-thiazolidine-4-carboxylic acid, enantiomerically pure **4** was prepared.¹¹ Substituted isoic anhydrides (like 5-chloroisoic anhydride) produced tricyclic benzodiazepindiones with approximately the same yield as that obtained with **1**. Our attempts to prepare derivatives of 2,2-dimethylthiazolidine-4-carboxylic acid were unsuccessful.

EXPERIMENTAL SECTION

Mps were determined using Thomas-Hoover capillary melting point apparatus and are uncorrected. All chemicals and solvents were obtained from commercial sources and used without purification. ¹H and ¹³C NMR spectra were collected on Bruker AC-300 NMR spectrometer; chemical shifts are reported with tetramethylsilane as an internal reference ($\delta_{\text{H,C}} = 0.0$ ppm). Spectra were acquired at ambient temperature in DMSO-*d*₆ or CDCl₃. Mass spectral analyses were performed on a Fisons instrument (Hewlett-Packard HPLC driven electrospray MS instrument). Analytical HPLC analyses were performed on a Hewlett-Packard liquid chromatography system (YMC column, 4 mm x 50 mm, 4 μm C₁₈, 1.0 mL/min, 8 min gradient from 95% aqueous media (0.1% TFA) to 95% CH₃CN (0.1% TFA), monitoring wavelength 220 and 260 nm).

General Procedure for Compounds 3 and 6.- A solution of thiazolidine carboxylic acid (1.33 g, 10 mmol) and isoic anhydride (1.63 g, 10 mmol) in 15 mL of a 4:1 (v/v) mixture of DMF:TEA was heated in a sealed tube for 2 h at 120°. The reaction mixture was cooled to room temperature and poured into cold water (300 mL), and the mixture was stirred for 2 hr. The white solid was collected, washed with water, and dried in a vacuum oven to provide benzodiazepinedione **3** (1.29 g, 55%). The compound was homogeneous by NMR and HPLC; analytically pure material was obtained by crystallization from methyl *t*-butyl ether.

Compound **3**: white crystals (from methyl *t*-butyl ether), mp. 208-210° (dec.); MS *m/z* 235 (M+H); NMR (300 MHz, DMSO-*d*₆) 10.6 (s, 1H), 7.80 (d, *J* = 7 Hz, 1H), 7.55 (t, *J* = 7 Hz, 1H), 7.25 (t, *J* = 8 Hz, 1H), 7.16 (d, *J* = 8 Hz, 1H), 4.67 (dd, *J* = 2, 10 Hz, 2H), 4.45 (dd, *J* = 2, 7 Hz, 1H), 3.60 (dd, *J* = 12, 3 Hz, 1H), 3.24 (dd, *J* = 5, 3 Hz, 1H). ¹³C NMR (75 MHz, DMSO-*d*₆) 169.9, 164.5, 136.7, 132.9, 130.9, 126.0, 124.3, 121.6, 58.5, 50.1, 31.1.

Anal. Calcd for C₁₁H₁₀N₂O₂S: C, 56.39; H, 4.30; N, 11.96. Found: C, 56.24; H, 4.53; N, 11.83

Since compound **6** did not precipitate from aqueous solution upon stirring, it was extracted into ether (3 x 50 mL). The combined organic layers were dried over MgSO₄ and evaporated. The brown solid residue was recrystallized from methyl *t*-butyl ether to provide **6** (0.70 g, 30%).

Compound **6**: white crystals (from methyl *t*-butyl ether), mp. 248-251° (dec.); MS *m/z* 235 (M+H); ¹H NMR (300 MHz, DMSO-*d*₆) 7.79 (d, *J* = 8 Hz, 1H), 7.54 (t, *J* = 6 Hz, 1H), 7.25 (t, *J* = 8 Hz, 1H), 7.14 (d, *J* = 8 Hz, 1H), 5.41 (s, 1H), 4.01-3.92 (m, 1H), 3.81-3.71 (m, 1H), 3.15-3.10 (m, 1H), 3.08-2.95 (m, 1H). ¹³C NMR (75 MHz, DMSO-*d*₆) 167.6, 164.2, 136.8, 132.8, 130.8, 126.5, 124.4, 121.7, 62.7, 50.6, 29.2.

Anal. Calcd for C₁₁H₁₀N₂O₂S: C, 56.39; H, 4.30; N, 11.96. Found: C, 56.25; H, 4.20; N, 11.87

General Procedure for Compounds 4 and 7. To a solution of benzodiazepinedione (**3** or **6**, 1.17 g, 5 mmol) in 50 mL of dry THF, cooled in an ice bath, was added dropwise LiAlH_4 (1.0 M in THF, 2.5 mL, 2.1 equiv) and the reaction mixture was heated to reflux. After 8 h, the solution was cooled to room temperature, and quenched by the sequential addition of 0.4 mL of water, 0.4 mL of 1 N NaOH, and 1.2 mL of water (**CAUTION**). The reaction mixture was filtered through Celite® and the filtrate was evaporated. The yellow solid concentrate was subjected to flash column chromatography (ethyl acetate) to provide the benzodiazepine **4** (80%) or **7** (65%).

Compound 4: white crystals (from methyl *t*-butyl ether), mp.225-228° (dec.), *lit.*⁹(from CHCl_3 -EtOH) mp 235.5-237°; MS m/z 207 (M+H); NMR (300 MHz, CDCl_3) 7.13-7.08 (m, 2H), 6.85 (t, $J = 7$ Hz, 1H), 6.72 (d, $J = 8$ Hz, 1H), 4.14-4.04 (m, 3H), 3.82 (broad s., 1H), 3.51 (d, $J = 14$ Hz, 1H), 3.41 (dd, $J = 4, 10$ Hz, 1H), 3.20-3.00 (m, 2H), 2.99-2.88 (m, 2H). ^{13}C NMR (75 MHz, $\text{DMSO}-d_6$) 151.3, 130.5, 127.8, 127.7, 119.4, 118.3, 69.6, 60.8, 55.6, 48.9, 32.3.

Anal. Calcd for $\text{C}_{11}\text{H}_{14}\text{N}_2\text{S}$: C, 64.04; H, 6.84; N, 13.58. Found: C, 63.88; H, 6.85; N, 13.44

Compound 7: white crystals (from methyl *t*-butyl ether), mp.112-115°; MS m/z 207 (M+H); ^1H NMR (300 MHz, CDCl_3) 6.93 (dd, $J = 13, 7$ Hz, 2H), 6.80 (t, $J = 7$ Hz, 1H), 6.68 (d, $J = 8$ Hz, 1H), 4.50 (dd, $J = 10, 4$ Hz, 1H), 4.25 (d, $J = 14$ Hz, 1H), 3.97 (broad s, 1H), 3.51-3.29 (m, 4H), 3.10-2.90 (m, 3H). ^{13}C NMR (75 MHz, $\text{DMSO}-d_6$) 149.9, 130.3, 127.6, 125.9, 118.4, 117.6, 74.7, 59.8, 54.2, 49.3, 30.7.

Anal. Calcd for $\text{C}_{11}\text{H}_{14}\text{N}_2\text{S}$: C, 64.04; H, 6.84; N, 13.58. Found: C, 64.00; H, 6.63; N, 13.55

REFERENCES

1. W. Hunkeler, E. Kuburz, Eur. Patent 195939 1986; *Chem. Abstr.*, **106**:84659 (1987).
2. Y. Ohtake, A. Naito, H. Hasegawa, K. Kawano, D. Morizono, M. Taniguchi, Y. Tanaka, H. Matsukawa, K. Naito, T. Oguma, Y. Ezure, Y. Tsuruya, *Bioorg. Med. Chem. Lett.*, **7**, 1247 (1999).
3. W. J. Hoekstra, A. B. Dyatkin, B. E. Maryanoff and J. M. Matthews, Patent WO 0043398 (1999); *Chem. Abstr.*, **133**:120350 (2000).
4. J. MacDonald, J. Matz, W. Shakespeare, Patent WO 9717344 (1996); *Chem. Abstr.*, **127**:50549 (1997).
5. B. E. Evan, M. G. Bock, *Adv. Med. Chem.*, **2**, 111 (1993)
6. D. E. Thurston, D. S. Bose, *Chem. Rev.*, **94**, 433 (1994)
7. B. Refouvelet, P. Tronche, J. Couquelet, J. F. Robert, G. Bonnefoy-Claudet, J. Panouse-Perrin, *Eur. J. Med. Chem.*, **22**, 11 (1987).
8. P. M. Carabateas, US Patent 3,860,600, 1975; *Chem. Abstr.*, **83**:58892 (1975).
9. P. M. Carabateas, US Patent 3,732,212, 1973; *Chem. Abstr.*, **79**:42570 (1973).

10. P. M. Carabateas, US Patent 3,763,183, 1973; *Chem. Abstr.*, **79**:546567 (1979).
11. The enantiomeric purity was determined by ^1H NMR with (+)-(*S*)-2,2,2-trifluoro-1-(9-anthryl)-ethanol as a chiral solvent. The corresponding (*R*)-enantiomer had $[\alpha]_{\text{D}}^{20} -113.8^\circ$ (*c* 0.488, CH_2Cl_2).

FACILE PREPARATION OF *trans*-2,3-bis(-*tert*-BUTYLAMINOMETHYL) NORBORNENE

Submitted by J. H. Wynne^{†,††} and W. M. Stalick*[†]
(04/25/02)

[†] Department of Chemistry, George Mason University
Fairfax, VA 22030, USA

^{††} Division of Chemistry, Naval Research Laboratory
Washington, DC 20375, USA

Norbornenes possessing sterically hindered amino pendant groups are a class of compounds used in the synthesis of novel advanced organic materials.¹ Polymers bearing amino and different heteroatom pendant groups are typically synthesized because they are able to chelate metals.² In addition, polymerization of compound **3**, where the bulky amino substituents are *t*-butyl groups, readily affords a material with a rigid backbone containing amine groups which have been shown to chelate to metals such as zinc and copper.³ These molecules have also been employed in polymers for their non-linear optical properties.^{3,4} The synthesis of diaminomethyl norbornene **3** has been reported in the literature albeit in only low to moderate yields.⁵ This lengthy four-step procedure involves a Diels-Alder reaction between cyclopentadiene and fumaric acid, followed by reduction to the *trans*-diol, subsequent treatment of the diol with tosyl chloride in pyridine to give the ditosylate, which upon reaction with *t*-butylamine in DMF at 100° for prolonged periods, in a sealed reaction vessel, resulted in the desired product **3**. This typically used method requires the use of a specialized reaction vessel at elevated temperature and pressure. We now report that compound **3** can be easily synthesized in high yields by a very simple facile approach resulting in both high purity and yields.

Treatment of freshly cracked cyclopentadiene, with *trans*-fumarionitrile afforded the Diels-Alder adduct **1** in quantitative yields as previously reported.⁶ Subsequent treatment under Ritter-type reaction conditions, employing *t*-butyl alcohol and conc. sulfuric acid in glacial acetic acid, transformed **1** to the di-*t*-butylamide **2**. This facile transformation can be performed in an Erlenmeyer flask and requires no inert atmosphere or special equipment. However, it is imperative that the temperature be maintained between 0 to 50° in order to prevent both ester and ether formation, which results if the temperature is not controlled.